Payment overview · 2025
General Payments
$400.59
6 reported records · 5 companies
Healthcare provider profile · identity verified
Reginald Dwayne Adams, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · RACINE, WI · NPI 1346278843
Verified facts
What the public records show
CMS Open Payments records show Reginald Dwayne Adams, D.O. received $400.59 in general payments during 2025 across 6 reported records.
COLOPLAST CORP accounted for 54.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| COLOPLAST CORP | Unresolved — no canonical attribution shown | $216.29 | 54.0% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$108.16 | 27.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.52 | 8.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.62 | 6.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.00 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $400.59 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Peristeen Normalized: peristeen |
Device | COLOPLAST CORP | $216.29 | 2 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $108.16 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.62 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
92 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 644 | 152 |
| Atorvastatin Calcium | Atorvastatin Calcium | 550 | 110 |
| Metoprolol Succinate | Metoprolol Succinate | 324 | 61 |
| Lisinopril | Lisinopril | 301 | 70 |
| Gabapentin | Gabapentin | 294 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 287 | 72 |
| Omeprazole | Omeprazole | 253 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 241 | 67 |
| Metformin Hcl | Metformin Hcl | 217 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 206 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 203 | 38 |
| Potassium Chloride | Potassium Chloride | 192 | 38 |
| Pregabalin | Pregabalin | 172 | 32 |
| Famotidine | Famotidine | 168 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 154 | 25 |
| Furosemide | Furosemide | 153 | 31 |
| Losartan Potassium | Losartan Potassium | 142 | 36 |
| Meloxicam | Meloxicam | 141 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 133 | 25 |
| Baclofen | Baclofen | 128 | 24 |
| Trazodone Hcl | Trazodone Hcl | 128 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 126 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 115 | 22 |
| Metformin Hcl Er | Metformin Hcl | 109 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 20 |
| Montelukast Sodium | Montelukast Sodium | 100 | 21 |
| Carvedilol | Carvedilol | 95 | 28 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 94 | 24 |
| Trulicity | Dulaglutide | 92 | 18 |
| Clonidine Hcl | Clonidine Hcl | 84 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 26 |
| Tramadol Hcl | Tramadol Hcl | 81 | 21 |
| Spironolactone | Spironolactone | 77 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 74 | 65 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 71 | 11 |
| Chlorthalidone | Chlorthalidone | 69 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 12 |
| Topiramate | Topiramate | 69 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 11 |
| Allopurinol | Allopurinol | 63 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | suppressed |
| Bupropion Xl | Bupropion Hcl | 62 | 11 |
| Ibuprofen | Ibuprofen | 61 | 21 |
| Eliquis | Apixaban | 60 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 14 |
| Sertraline Hcl | Sertraline Hcl | 58 | 11 |
| Clonidine | Clonidine | 57 | 11 |
| Simvastatin | Simvastatin | 55 | 11 |
| Ozempic | Semaglutide | 54 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 53 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 50 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 50 | 11 |
| Linzess | Linaclotide | 50 | 11 |
| Alendronate Sodium | Alendronate Sodium | 47 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 46 | 12 |
| Jardiance | Empagliflozin | 45 | suppressed |
| Naproxen | Naproxen | 44 | 13 |
| Glipizide Er | Glipizide | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Mirtazapine | Mirtazapine | 36 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 31 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Colchicine | Colchicine | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 29 | 29 |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Epinephrine | Epinephrine | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Olanzapine Odt | Olanzapine | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 11 |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Prednisone | Prednisone | 13 | 11 |
| Acamprosate Calcium | Acamprosate Calcium | 12 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Nicotrol Ns | Nicotine | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $400.59 · 6 records | COLOPLAST CORP | Cologuard Collection Kit, INTELLIS ADAPTIVESTIM, MOUNJARO, Peristeen | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error